(A) Experimental protocol used for evaluating the effect of NKG2D–NKG2D-L interactions in the BMF induced by MMC in Fanca^–/– mice. Mice were periodically treated with an isotype control or an anti-NKG2D mAb, prior to and after initiating MMC treatment (2 doses of 0.3 mg/kg). PB samples from Fanca^–/– mice were obtained prior to and after treatment. (B) Representative flow cytometric analysis showing expression of NKG2D-Ls in Lin^–c-Kit⁺ cells from Fanca^–/– mice treated with MMC compared with expression in untreated mice. (C) Proportion of Lin^–c-Kit⁺ cells and LSK cells positive for NKG2D-Ls at the end of the experimental protocol (day 14) in untreated or MMC-treated Fanca^–/– mice receiving the isotype control or the anti-NKG2D antibody. (D) Proportion of NK cells and CD8⁺ and CD4⁺ T cells, and their respective activated subpopulations in mononuclear BM cells from Fanca^–/– mice treated as in C. (E) Comparative analysis of PB cell parameters in MMC-treated Fanca^–/– mice that received the isotype control (blue dots) or the anti-NKG2D mAB (red dots). Each dot shows changes in PB parameters on days 7 and 14 after MMC treatment with respect to the values determined on day –4 (prior to starting mAb and MMC treatments), which were considered as 100%. The mean PB values corresponding to the isotype control– and the anti-NKG2D–treated groups on day –4 were, respectively, hemoglobin: 14.53 and 13.38 g/dL; RBCs: 10.37 and 9.32 × 10⁶ cells/μL; WBCs: 4.64 and 5.08 × 10³ cells/μL; platelets: 1002 and 914 × 10³ cells/μL. The Mann-Whitney U test was used to compare day 7 mean values and an unpaired t test to compare day 14 mean values according to the respective data distributions. Whiskers represent the minimum and maximum values, the lower and upper box edges correspond to the 25th and 75th percentiles, respectively, and the lines within the boxes correspond to the median.